JPMorgan chimes in on Edward Lifesciences (EW -0.9%), noting that a FDA panel delay on Sapein...

|By:, SA News Editor

JPMorgan chimes in on Edward Lifesciences (EW -0.9%), noting that a FDA panel delay on Sapein until June will keep the suspense in place for an extra month on the outcome for broader use of the heart valve. Analysts with JP have a Neutral rating on the company.